| Literature DB >> 26885251 |
Dorota Drożdż1, Przemko Kwinta2, Krystyna Sztefko3, Zbigniew Kordon4, Tomasz Drożdż5, Monika Łątka1, Monika Miklaszewska1, Katarzyna Zachwieja1, Andrzej Rudziński4, Jacek Antoni Pietrzyk1.
Abstract
Cardiovascular diseases remain the most frequent cause of morbidity and mortality in patients with chronic kidney disease (CKD). The aim of the study was to assess the association between oxidative stress biomarkers and cardiovascular risk factors and left ventricular hypertrophy in children with CKD. Material and Methods. The studied group consisted of 65 patients aged 1.4-18.6 (mean 11.2) years with stages 1 to 5 CKD. Serum oxidized low-density lipoprotein (oxLDL), protein carbonyl group, creatinine, cystatin C, albumin, lipids, high-sensitivity C-reactive protein, intercellular adhesion molecule-1, insulin, plasma renin activity, and aldosterone levels were measured. Patients were divided into groups depending on CKD stage. Anthropometric measurements, ambulatory blood pressure (BP) measurements, and echocardiography with left ventricular mass (LVM) calculation were performed. Results. Serum oxLDL strongly correlated with creatinine (R = 0.246; p = 0.048), cystatin C (R = 0.346; p = 0.006), total cholesterol (R = 0.500; p < 0.001), triglycerides (R = 0.524; p < 0.001), low-density lipoprotein concentrations (R = 0.456; p < 0.001), and 24 hour BP values of systolic (R = 0.492; p = 0.002), diastolic (R = 0.515; p < 0.001), and mean arterial pressure (R = 0.537; p < 0.001). A significant correlation between oxLDL levels and LVM z-scores (R = 0.299; p = 0.016) was found. Conclusions. Hypertension and dyslipidemia correlated with lipid oxidation in children with CKD. oxLDLs seem to be valuable markers of oxidative stress in CKD patients, correlating with left ventricular hypertrophy.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26885251 PMCID: PMC4739446 DOI: 10.1155/2016/7520231
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Basic clinical data and kidney function parameters depending on CKD stage in the investigated group of 65 patients.
| Parameter | CKD stage |
| |||
|---|---|---|---|---|---|
| 1 + 2 | 3 | 4 | 5 | ||
| Age (years) | 10.51 | 11.33 | 12.01 | 11.61 | 0.820 |
|
| |||||
| Height ( | 0.078 | −0.716 | −0.868 | −1.495 |
|
|
| |||||
| Body mass ( | −0.015 | −0.980 | −0.464 | −1.587 |
|
|
| |||||
| BMI (kg/m2) | 16.5 | 16.6 | 18.1 | 15.9 | 0.224 |
|
| |||||
| BMI ( | 0.316 | −0.779 | 0.079 | −1.252 |
|
|
| |||||
| Creatinine ( | 69.3 | 113.8 | 274.9 | 501.8 |
|
|
| |||||
| Cystatin C (mg/L) | 0.86 | 1.45 | 2.6 | 4.81 |
|
|
| |||||
| eGFR Filler | 109.46 | 60.13 | 29.49 | 14.77 |
|
Values presented as median (25th–75th percentile).
BMI—body mass index; eGFR—estimated glomerular filtration rate.
Statistically significant differences between stages 1 + 2 and 4, 1 + 2 and 5.
Statistically significant differences between stages 1 + 2 and 3, 1 + 2 and 5, 4 and 5.
Statistically significant differences between stages 4 and 5.
Statistically significant differences between all stages.
Selected parameters depending on CKD stage in the investigated group of 65 patients.
| Parameter | CKD stage |
| |||
|---|---|---|---|---|---|
| 1 + 2 | 3 | 4 | 5 | ||
| hsCRP (ng/mL) | 171.6 | 252.4 | 338.9 | 365.6 | 0.397 |
|
| |||||
| Carbonyl groups (nmol/mg) | 1.15 | 1.24 | 1.64 | 1.23 | 0.454 |
|
| |||||
| oxLDL (U/L) | 80.65 | 75.81 | 82.31 | 98.89 |
|
|
| |||||
| Aldosterone (pg/mL) | 186.1 | 272.8 | 471.00 | 192.3 | 0.250 |
|
| |||||
| PRA (ng/mL/h) | 4.99 | 6.88 | 4.69 | 3.88 | 0.521 |
|
| |||||
| ICAM-1 (ng/mL) | 305.7 | 319.1 | 322.1 | 329.2 | 0.922 |
|
| |||||
| Insulin ( | 9.0 | 9.5 | 12.8 | 13.1 | 0.162 |
|
| |||||
| Albumin (g/L) | 45.0 | 45.50 | 46.8 | 44.1 | 0.127 |
Values presented as median (25th–75th percentile)
hsCRP—high sensitive C-reactive protein; oxLDL—oxidized low-density lipoprotein; PRA—plasma renin activity; ICAM-1—intercellular adhesion molecule-1.
Statistically significant differences between stages 3 and 5.
Investigated clinical, biochemical, and echocardiographic parameters in the groups with oxLDL quartiles.
| Parameter | oxLDL (U/L) |
| |||
|---|---|---|---|---|---|
| 41.4–67.4 | 67.5–84.8 | 86.0–103.5 | 103.6–176.1 | ||
| SBP 24 h ( | 0.11 | −0.62 | −0.33 | 1.86 |
|
|
| |||||
| DBP 24 h ( | −0.06 | −0.77 | −0.46 | 2.42 |
|
|
| |||||
| MAP 24 h ( | 0.42 | −0.32 | 0.00 | 2.32 |
|
|
| |||||
| Total chol. (mmol/L) | 4.19 | 4.48 | 4.67 | 6.19 |
|
|
| |||||
| TGL (mmol/L) | 1.21 | 1.30 | 1.69 | 2.62 |
|
|
| |||||
| HDL (mmol/L) | 1.35 | 1.35 | 1.19 | 1.26 | 0.417 |
|
| |||||
| LDL (mmol/L) | 2.07 | 2.43 | 2.49 | 3.26 |
|
|
| |||||
| Cystatin (mg/L) | 1.36 | 2.36 | 2.55 | 4.24 | 0.053 |
|
| |||||
| Albumin (g/L) | 46.0 | 46.0 | 45.0 | 43.0 | 0.320 |
|
| |||||
| hsCRP (ng/mL) | 267.5 | 321.9 | 459.2 | 273.2 | 0.939 |
|
| |||||
| ICAM-1 (ng/mL) | 295.5 | 303.0 | 339.9 | 326.4 (278.4; 396.7) | 0.373 |
|
| |||||
| Carbonyl groups (nmol/mg) | 1.39 | 1.73 | 1.23 | 0.92 | 0.736 |
|
| |||||
| LVM ( | 0.05 | −0.27 | 0.73 | 1.01 |
|
|
| |||||
| LVEDd | 0.17 | 0.19 | −0.03 | 0.22 | 0.765 |
|
| |||||
| IVSd | 0.99 | 0.31 | 1.06 | 1.08 | 0.082 |
|
| |||||
| LVPWT | 0.75 | 1.32 | 1.40 | 1.45 | 0.281 |
Values presented as median (25th–75th percentile).
SBP 24 h—systolic blood pressure 24 h; DBP 24 h—diastolic blood pressure 24 h; MAP 24 h—mean arterial pressure 24 h; TGL—triglycerides; HDL—high-density lipoprotein; LDL—low-density lipoprotein; hsCRP—high sensitive C-reactive protein; oxLDL—oxidized low-density lipoprotein; ICAM-1—intercellular adhesion molecule-1; LVM—left ventricular mass; LVEDd—left ventricular end-diastolic dimension; IVSd—interventricular septum at end diastole; LVPWd— left ventricular posterior wall thickness at end diastole.
Figure 1Scatterplot presenting the correlation between oxLDL concentrations and left ventricular mass (LVM) (z-score).